House Bill 830
By: Representatives Harden of the 148th, Stephens of the 164th, Parrish of the 158th, and Taylor of the 173rd

A BILL TO BE ENTITLED
AN ACT

To amend Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, so as to change certain provisions relating to Schedules I and II controlled substances; to change certain provisions relating to the definition of dangerous drug; to provide for related matters; to provide an effective date; to repeal conflicting laws; and for other purposes.

BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

SECTION 1.
Chapter 13 of Title 16 of the Official Code of Georgia Annotated, relating to controlled substances, is amended in Code Section 16-13-25, relating to Schedule I controlled substances, by adding a new subparagraph to paragraph (3) to read as follows:

"(GGGG) Fluorophenmetrazine;"

SECTION 2.
Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising division (ii) of subparagraph (L) of paragraph (12) as follows:

"(ii) By substitution at the 3-position with an acyclic alkyl substitution or alkoxy substitution; or"

SECTION 3.
Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising division (ii) of subparagraph (E) of paragraph (13) as follows:

"(ii) Acetamide group, which itself can be further substituted with:
(I) Cyclic acyclic alkyl group;
(II) Tetrahydrofuran group;"
SECTION 4.
Said chapter is further amended in Code Section 16-13-25, relating to Schedule I controlled substances, by revising the introductory text of paragraph (15) as follows:

"(15) The 1-cyclohexyl-4-(1,2-diphenylethyl diphenylethyl)-piperazine (MT-45) structural class, including any of the following derivatives, their salts, isomers, or salts of isomers, unless specifically utilized as part of the manufacturing process by a commercial industry of a substance or material not intended for human ingestion or consumption, as a prescription administered under medical supervision, or for research at a recognized institution, whenever the existence of these salts, isomers, or salts of isomers is possible within the specific chemical designation or unless specifically excepted or listed in this or another schedule, structurally derived from 1-cyclohexyl-4-(1,2-diphenylethyl diphenylethyl)-piperazine (MT-45), and whether or not further modified in any of the following ways:"

SECTION 5.
Said chapter is further amended in Code Section 16-13-26, relating to Schedule II controlled substances, by substituting the "." at the end of paragraph (4) with a ";" and by adding a new paragraph to read as follows:

"(5) Dronabinol in oral solution labeled in compliance with U.S. Food and Drug Administration requirements."

SECTION 6.
Said chapter is further amended in Code Section 16-13-71, relating to the definition of "dangerous drug," by adding new paragraphs to subsection (b) to read as follows:

"(.031) Abaloparatide;"
"(.041) Abemaciclib;"
"(.044) Acalabrutinib;"
"(51.5) Angiotensin II;"
"(69.11) Avelumab;"
"(83.11) Benralizumab;"
"(84.1) Benznidazole;"
"(97.11) Betrixaban;"
"(107.4) Brigatinib;"
"(107.6) Brodalumab;"
"(159.9) Cerliponase alfa;"
"(213.4) Copanlisib;"
"(244.3) Deflazacort;"
"(244.41) Delafloxacin;
(256.6) Deutetrabenazine;
(325.46) Dupilumab;
(325.47) Durvalumab;
(330.4) Edaravone;
(331.0701) Emicizumab;
(331.7) Enasidenib;
(346.7) Ertugliflozin
(355.7) Etelcalcetide;
(415.04) Glecaprevir;
(432.91) Guselkumab;
(474.1) Inotuzumab ozogamicin;
(512.8) Latanoprostene bunod;
(513.78) Letermovir;
(534.3) Macimorelin;
(617.2) Midostaurin;
(632.1) Naldemedine;
(640.11) Neratinib maleate;
(640.25) Netarsudil
(644.61) Niraparib;
(661.2) Ocrelizumab;
(680.3) Ozenoxacin;
(731.01) Pibrentasvir
(742.1) Plecanatide;
(838.6) Ribociclib;
(849.8) Safinamide;
(851.2) Sarilumab;
(852.06) Secnidazole;
(853.9) Semaglutide;
(931.61) Telotristat ethyl;
(1021.61) Vaborbactam;
(1021.71) Valbenazine;
(1029.6) Vestronidase alfa-vjbk;
(1037.9) Voxilaprevir;
SECTION 7.
Said chapter is further amended in Code Section 16-13-71, relating to the definition of "dangerous drug," by revising paragraph (516.75) of subsection (b) as follows:

"(516.75) Levocetirizine — See exceptions;"

SECTION 8.
Said chapter is further amended in Code Section 16-13-71, relating to the definition of "dangerous drug," by adding a paragraph in subsection (c) to read as follows:

"(12.91) Levocetirizine — when a single dose unit is either 2.5 mg. per 5 ml. or less or 5 mg. or less;"

SECTION 9.
Said chapter is further amended in Code Section 16-13-71, relating to the definition of "dangerous drug," by amending paragraph (13) in subsection (c) to read as follows:

"(13) Lidocaine topical, ointment, 25 mg./gm. 40 mg./gm. (4%) or less;"

SECTION 10.
This Act shall become effective upon its approval by the Governor or upon its becoming law without such approval.

SECTION 11.
All laws and parts of laws in conflict with this Act are repealed.